MLICM
STRO icon

Metropolitan Life Insurance Company (MetLife)’s Sutro Biopharma STRO Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-163
Closed -$9.22K – 1860
2024
Q1 		$9.22K Buy
163
+54
+50% +$2.38K ﹤0.01% 2158
2023
Q4 		$4.66K Sell
109
-186
-63% -$5.9K ﹤0.01% 2290
2023
Q3 		$10.2K Hold
295
– – ﹤0.01% 2192
2023
Q2 		$13.7K Hold
295
– – ﹤0.01% 2128
2023
Q1 		$13.6K Sell
295
-3
-1% -$190 ﹤0.01% 2048
2022
Q4 		$24.1K Hold
298
– – ﹤0.01% 1907
2022
Q3 		$16.5K Buy
298
+260
+684% +$15.4K ﹤0.01% 2116
2022
Q2 		$1.96K Sell
38
-257
-87% -$14.4K ﹤0.01% 2359
2022
Q1 		$24.2K Sell
295
-688
-70% -$65.5K ﹤0.01% 2003
2021
Q4 		$146K Sell
983
-288
-23% -$51.6K ﹤0.01% 2237
2021
Q3 		$240K Buy
1,271
+68
+6% +$12.9K ﹤0.01% 1937
2021
Q2 		$224K Buy
1,203
+339
+39% +$66.3K ﹤0.01% 2063
2021
Q1 		$197K Hold
864
– – ﹤0.01% 2031
2020
Q4 		$188K Hold
864
– – ﹤0.01% 1978
2020
Q3 		$86.8K Buy
+864
New +$81.6K ﹤0.01% 2294

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s STRO Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Sutro Biopharma (STRO) in Q2 2024, closing a stake of 163 shares — an estimated $9.22K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in STRO in Q3 2020 and held it in 15 quarters. The position peaked at $240K in Q3 2021. 119 funds tracked by Wall St. Rank hold STRO as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Sutro Biopharma position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 163 Sutro Biopharma shares in Q2 2024, an estimated $9.22K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Sutro Biopharma in Q3 2020 and held it in 15 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Sutro Biopharma position peaked at $240K in Q3 2021.
  • 119 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.